These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 27775705)

  • 1. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.
    Horiuchi D; Camarda R; Zhou AY; Yau C; Momcilovic O; Balakrishnan S; Corella AN; Eyob H; Kessenbrock K; Lawson DA; Marsh LA; Anderton BN; Rohrberg J; Kunder R; Bazarov AV; Yaswen P; McManus MT; Rugo HS; Werb Z; Goga A
    Nat Med; 2016 Nov; 22(11):1321-1329. PubMed ID: 27775705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.
    Brasó-Maristany F; Filosto S; Catchpole S; Marlow R; Quist J; Francesch-Domenech E; Plumb DA; Zakka L; Gazinska P; Liccardi G; Meier P; Gris-Oliver A; Cheang MC; Perdrix-Rosell A; Shafat M; Noël E; Patel N; McEachern K; Scaltriti M; Castel P; Noor F; Buus R; Mathew S; Watkins J; Serra V; Marra P; Grigoriadis A; Tutt AN
    Nat Med; 2016 Nov; 22(11):1303-1313. PubMed ID: 27775704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of p27 and c-Myc by immunohistochemistry in breast ductal cancers in African American women.
    Khan F; Ricks-Santi LJ; Zafar R; Kanaan Y; Naab T
    Ann Diagn Pathol; 2018 Jun; 34():170-174. PubMed ID: 29715580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
    Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
    Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting PML in triple negative breast cancer elicits growth suppression and senescence.
    Arreal L; Piva M; Fernández S; Revandkar A; Schaub-Clerigué A; Villanueva J; Zabala-Letona A; Pujana M; Astobiza I; Cortazar AR; Hermanova I; Bozal-Basterra L; Arruabarrena-Aristorena A; Crespo JR; Valcarcel-Jimenez L; Zúñiga-García P; Canals F; Torrano V; Barrio R; Sutherland JD; Alimonti A; Martin-Martin N; Carracedo A
    Cell Death Differ; 2020 Apr; 27(4):1186-1199. PubMed ID: 31570853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.
    Horiuchi D; Kusdra L; Huskey NE; Chandriani S; Lenburg ME; Gonzalez-Angulo AM; Creasman KJ; Bazarov AV; Smyth JW; Davis SE; Yaswen P; Mills GB; Esserman LJ; Goga A
    J Exp Med; 2012 Apr; 209(4):679-96. PubMed ID: 22430491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
    Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
    Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.
    Rebello RJ; Kusnadi E; Cameron DP; Pearson HB; Lesmana A; Devlin JR; Drygin D; Clark AK; Porter L; Pedersen J; Sandhu S; Risbridger GP; Pearson RB; Hannan RD; Furic L
    Clin Cancer Res; 2016 Nov; 22(22):5539-5552. PubMed ID: 27486174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
    Camarda R; Zhou AY; Kohnz RA; Balakrishnan S; Mahieu C; Anderton B; Eyob H; Kajimura S; Tward A; Krings G; Nomura DK; Goga A
    Nat Med; 2016 Apr; 22(4):427-32. PubMed ID: 26950360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIM1: a promising target in patients with triple-negative breast cancer.
    Zhao W; Qiu R; Li P; Yang J
    Med Oncol; 2017 Aug; 34(8):142. PubMed ID: 28721678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
    Kim J; Roh M; Abdulkadir SA
    BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer.
    Kunder R; Velyunskiy M; Dunne SF; Cho BK; Kanojia D; Begg L; Orriols AM; Fleming-Trujillo E; Vadlamani P; Vialichka A; Bolin R; Perrino JN; Roth D; Clutter MR; Zielinski-Mozny NA; Goo YA; Cristofanilli M; Mendillo ML; Vassilopoulos A; Horiuchi D
    Cell Chem Biol; 2022 Mar; 29(3):358-372.e5. PubMed ID: 34525344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIM1 is responsible for IL-6-induced breast cancer cell EMT and stemness via c-myc activation.
    Gao X; Liu X; Lu Y; Wang Y; Cao W; Liu X; Hu H; Wang H
    Breast Cancer; 2019 Sep; 26(5):663-671. PubMed ID: 30989585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
    Li M; Li A; Zhou S; Lv H; Yang W
    J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells.
    Mehta R; Katta H; Alimirah F; Patel R; Murillo G; Peng X; Muzzio M; Mehta RG
    PLoS One; 2013; 8(6):e65113. PubMed ID: 23762292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers.
    Song W; Hwang Y; Youngblood VM; Cook RS; Balko JM; Chen J; Brantley-Sieders DM
    Oncogene; 2017 Oct; 36(40):5620-5630. PubMed ID: 28581527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GNA13 suppresses proliferation of ER+ breast cancer cells via ERα dependent upregulation of the MYC oncogene.
    Subramanyan LV; Rasheed SAK; Wang L; Ghosh S; Ong MSN; Lakshmanan M; Wang M; Casey PJ
    Breast Cancer Res; 2024 Jul; 26(1):113. PubMed ID: 38965558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TOP1 inhibition induces bifurcated JNK/MYC signaling that dictates cancer cell sensitivity.
    Liu Q; Chung S; Murata MM; Han B; Gao B; Zhang M; Lee TY; Chirshev E; Unternaehrer J; Tanaka H; Giuliano AE; Cui Y; Cui X
    Int J Biol Sci; 2022; 18(10):4203-4218. PubMed ID: 35844787
    [No Abstract]   [Full Text] [Related]  

  • 20. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
    Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.